



TML: CS: 2018-19:

12th July, 2018

Listing Department
BSE Limited.
P. J. Towers, Dalal Street
Mumbai-400001.

Listing Department,
National Stock Exchange of India Ltd.
"Exchange Plaza", Bandra – Kurla
Complex,
Bandra – East, Mumbai- 400 051.

Sir/Madam,

Sub: Letter received from FDA Authorities.

Ref: 1. Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
2. BSE Scrip Code: 530199
3. NSE Scrip Code: THEMISMED


Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we, hereby, inform you that the Company has received a letter dated 11th July, 2018 from the Food and Drug Administration (FDA) authorities directing, inter alia, not to manufacture a key product till deciding of the matter. The Company has been given an opportunity to be heard and is taking necessary steps to suitably reply to the said letter. The product is being manufactured and marketed by the Company as also supplied to a Pharma Company on Principal to Principal basis. The Company, being aggrieved by the developments, has filed a Writ Petition in the Hon'ble Delhi High Court in this connection and the same has been admitted by the Hon'ble Delhi High Court.

This may be taken as a disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015.

The Company will keep the Stock Exchange informed of any further developments in this matter.

Thanking You,

Yours faithfully,
For **THEMIS MEDICARE LIMITED**


Dr. Sachin D. Patel
Managing Director & CEO
DIN: 00033353



Themis Medicare Limited

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104. India

Tel. : 91-22-6760 7080 • **Fax :** 91-22-6760 7070 / 2874 6621

Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat.

CIN No.: L24110GJ1969PLC001590 • **Tel / Fax No.:** **Regd. Off. :** 0260 2431447 / 2430219

• **E-mail :** themis@themismedicare.com • **Website :** www.themismedicare.com